TipRanks
Go Ultimate55% OFF

VITA 34 (V3V) Price & Analysis

V3V Stock Chart & Stats

€2.78-€0.01(-0.36%)
At close: 4:00 PM EDT
EUR 2.75EUR 33 Aug17 Aug31 Aug14 Sep28 Sep12 Oct27 Oct
Day’s Range
EUR 2.78 - EUR 2.79
52-Week Range
EUR 2.58 - EUR 7.15
Previous Close
EUR 2.79
Volume
1,201
Average Volume (3M)
1,226
Market Cap
EUR 48.46M
Enterprise Value
EUR 73.56M
Total Cash (Recent Filing)
EUR 12.45M
Total Debt (Recent Filing)
EUR 23.03M
Price to Earnings (P/E)
―
Beta
0.15
Next Earnings
Nov 30, 2026
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Recurring Biobanking Revenue

The combination of upfront processing income and recurring storage fees gives VITA 34 a more durable revenue base than a purely transactional service. Active contracts can continue generating fees over many years, supporting customer retention, revenue visibility, and operating planning.

Improving Revenue And Margins

Strong TTM revenue growth alongside a gross-margin recovery and positive EBITDA indicates meaningful operating improvement. If maintained, this combination can increase contribution from the existing business, support reinvestment, and improve the path toward sustainable profitability.

Positive Recent Cash Generation

Positive operating and free cash flow provide internally generated funding for ongoing operations and reduce immediate reliance on external capital. This is an important fundamental strength because cash generation has improved even while reported net income remains negative.

Bears Say

Ongoing Net Losses

Persistent operating and net losses weaken earnings quality and limit the company’s ability to build equity through retained profits. Until profitability improves, cash generation may not translate into durable earnings strength, leaving the business more exposed to execution setbacks.

High Leverage And Thin Equity

A sharply higher debt-to-equity ratio and small equity cushion reduce financial flexibility relative to the asset base. This structure can constrain investment choices, increase sensitivity to operating weakness, and make balance-sheet repair dependent on improved results or additional capital.

Volatile Cash-flow Consistency

Recent positive cash flow is encouraging, but the history of negative operating cash flow and sharply negative latest free-cash-flow growth indicates an unstable run-rate. Inconsistent conversion can complicate funding decisions and reduce confidence that current cash generation will persist.

V3V FAQ

What was VITA 34’s price range in the past 12 months?
VITA 34 lowest stock price was €2.58 and its highest was €7.15 in the past 12 months.
What is VITA 34’s market cap?
VITA 34’s market cap is €48.46M.
When is VITA 34’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were VITA 34’s earnings last quarter?
VITA 34 released its earnings results on Aug 28, 2026. The company reported -€0.064 earnings per share for the quarter.
Is VITA 34 overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does VITA 34 pay dividends?
VITA 34 pays a Annually dividend of €0.16 which represents an annual dividend yield of ―. See more information on VITA 34 dividends here
What is VITA 34’s EPS estimate?
VITA 34’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VITA 34 have?
VITA 34 has 17,640,104 shares outstanding.
What happened to VITA 34’s price movement after its last earnings report?
VITA 34 reported an EPS of -€0.064 in its last earnings report. Following the earnings report the stock price went up 2.448%.
Which hedge fund is a major shareholder of VITA 34?
Currently, no hedge funds are holding shares in DE:V3V
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology